Early October 2019, the European Medicines Agency (EMA), together with the European medicines authorities, including the FAMHP, asked all marketing authorisation holders to perform a risk assessment on the presence of nitrosamines as a precaution. The result of this risk assessments (step 1) must be reported via the particular web form before 1 October 2020. Another particular web form is available for submitting the results of the confirmatory tests (step 2).
The new BelVet-SAC report which contains an overview of the use of antibiotics in veterinary medicine is available. The 2019 results confirm the trends of previous years with consumption down 7.8% for mg of active substance/kg of biomass compared to last year. Compared to the 2011 reference year, the use of antibiotics in veterinary medicine has decreased by 40.3%.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals and pharmacies facing difficulties in securing supplies of medicinal products. Here is an overview of the measures put in place by the FAMHP to guarantee stocks of medicinal products in Belgium.
Since the start of the coronavirus pandemic, the FAMHP teams have devoted a lot of resources to monitoring and supporting clinical research on COVID-19. Here is an overview of the measures implemented by the FAMHP.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals facing difficulties with supplies of medical devices. Here is an overview of the measures implemented by the FAMHP.
Due to a worldwide increase in demand for the Gardasil 9 vaccine, used to prevent Human Papillomavirus (HPV), stocks of this vaccine are currently limited in Belgium. This limited availability has been extended and should continue until September 2020. The Federal Agency for Medicines and Health Products (FAMHP) has updated the recommendations for prescribers.
The Federal Agency for Medicines and Health Products (FAMHP) has authorized the first clinical trial evaluating a vaccine against COVID-19 in Belgium. This is the candidate vaccine from the German biotech firm CureVac.